Literature DB >> 1938243

Local BCG therapy of superficial bladder tumours.

J Kondás1, E Szentgyörgyi, L Szecsö, G Kondér.   

Abstract

A total of 126 patients, whose superficial bladder tumours (Ta-Tl) had been removed by TUR, were subjected to local BCG therapy. Marked by frequent though mild side effects, they presented a significantly lower rate of tumour recurrence than the control group under exclusive TUR treatment. During a follow-up period of 3 years, 74% of the patients proved recurrence-free. BCG and Adriamycin were found largely similar in degree of effectiveness.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1938243     DOI： 10.1007/bf02583987

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


  13 in total

1.  Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.

Authors:  D R Kelley; T L Ratliff; W J Catalona; A Shapiro; J M Lage; W C Bauer; E O Haaff; S M Dresner
Journal:  J Urol       Date:  1985-07       Impact factor: 7.450

2.  Bacillus Calmette-Guerin immunotherapy for bladder cancer.

Authors:  D L Lamm
Journal:  J Urol       Date:  1985-07       Impact factor: 7.450

3.  Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.

Authors:  E O Haaff; S M Dresner; T L Ratliff; W J Catalona
Journal:  J Urol       Date:  1986-10       Impact factor: 7.450

4.  Bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder.

Authors:  P F Schellhammer; L E Ladaga; M B Fillion
Journal:  J Urol       Date:  1986-02       Impact factor: 7.450

5.  Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer.

Authors:  D L Lamm; V D Stogdill; B J Stogdill; R G Crispen
Journal:  J Urol       Date:  1986-02       Impact factor: 7.450

6.  Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guerin.

Authors:  D R Kelley; E O Haaff; M Becich; J Lage; W C Bauer; S M Dresner; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1986-02       Impact factor: 7.450

7.  Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder.

Authors:  H W Herr; C M Pinsky; W F Whitmore; P C Sogani; H F Oettgen; M R Melamed
Journal:  J Urol       Date:  1986-02       Impact factor: 7.450

8.  BCG immunotherapy of bladder cancer: inhibition of tumor recurrence and associated immune responses.

Authors:  D L Lamm; D E Thor; W D Winters; V D Stogdill; H M Radwin
Journal:  Cancer       Date:  1981-07-01       Impact factor: 6.860

9.  Local adriamycin treatment for prevention of recurrence of superficial bladder tumours.

Authors:  J Kondás; E Szentgyörgyi; D Szöke
Journal:  Int Urol Nephrol       Date:  1988       Impact factor: 2.370

10.  Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma.

Authors:  S A Brosman
Journal:  J Urol       Date:  1982-07       Impact factor: 7.450
View more
  1 in total

1.  Transurethral resection of 1250 bladder tumours.

Authors:  J Kondás; E Szentgyörgyi
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.